Olaparib, Pembrolizumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-29 in 7d
ESTIMATED |
READOUT
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the T
Phase 2 · Solid Tumors |
Merck Sharp & Dohme LLC | Olaparib, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|